Meadowsweet, Salicylates and the Aspirin Story

Distilling meadowsweet flowers, as chemists did in the 1830s
Distilling meadowsweet flowers, as chemists did in the 1830s

There is a true and genuinely delightful fact about meadowsweet: the word aspirin is named partly after it. There is also a false claim that grows out of that fact like a weed — that aspirin "comes from meadowsweet," or that meadowsweet tea is "herbal aspirin." Both the true part and the false part matter, because the difference between them is the difference between a fragrant meadow tea and a drug that inhibits your platelets for the life of the cell. This page separates the two carefully. It is the most useful thing anyone can tell you about this plant.

Table of Contents

  1. What the Plant Actually Contains
  2. Where the "-spir-" in Aspirin Comes From
  3. Two Plants, One Molecule
  4. Glycosides, Not Aspirin
  5. What Acetylation Actually Does
  6. Why "Herbal Aspirin" Is a Category Error
  7. Not a Substitute for Low-Dose Aspirin
  8. The Dose Nobody Can Tell You
  9. What Each Claim Actually Rests On
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What the Plant Actually Contains

Meadowsweet is Filipendula ulmaria, a tall perennial of wet European meadows in the rose family (Rosaceae). The parts used are the flowering tops — the creamy flower sprays and the upper leaves. Crush them and you get a scent between wintergreen and almond, and that smell is a direct chemical readout of what is inside.

The salicylate-related constituents fall into three groups:

Alongside them sit constituents that have nothing to do with aspirin and are just as relevant to how the herb behaves: ellagitannins (astringent polyphenols, including rugosin-type compounds) in quantity, flavonoids including spiraeoside (quercetin 4′-O-glucoside, named after the plant), quercetin, hyperoside, rutin and kaempferol glycosides, plus phenolic acids and a little mucilage.

Read that list once more and note what is not on it: acetylsalicylic acid. The plant does not make it. No plant makes it. It has never been found in meadowsweet, willow, or any other botanical source, because acetylsalicylic acid is a laboratory modification of a plant molecule, not a plant molecule.

Where the "-spir-" in Aspirin Comes From

This part is real, and it is worth telling properly.

Meadowsweet's older botanical name was Spiraea ulmaria. Linnaeus placed it in Spiraea, the genus that also holds the ornamental garden spiraeas. Later taxonomists moved it out into Filipendula on the basis of its fruit and flower structure, which is why every modern source writes Filipendula ulmaria (L.) Maxim. — the "(L.)" preserving Linnaeus's original naming and "Maxim." crediting the botanist who made the transfer. The old name survives in the chemistry and the pharmacy, not the botany.

In the 1830s, chemists distilling meadowsweet flowers recovered the fragrant aldehyde and, by oxidising it, an acid. Because the source plant was Spiraea, they called the acid Spirsäure — spiraeic acid. Meanwhile chemists working on willow (Salix) had isolated a bitter glycoside they called salicin, after the willow genus, and from it obtained an acid they called salicylic acid. It took a little while to establish what is now obvious: spiraeic acid and salicylic acid are the same compound. Two names, two plants, one molecule. Salicylic acid won the naming contest for the compound; Spiraea won it for the drug.

When Bayer marketed the acetylated version in 1899, the trade name was assembled from pieces:

So the etymology genuinely runs through this plant. A humble meadow flower is embedded in the name of the most widely taken drug in human history. That is a legitimately remarkable piece of botanical trivia, and nothing on this page is meant to take it away from you.

Two Plants, One Molecule

The popular version of the story usually picks a single hero — either willow bark or meadowsweet — and gives it all the credit. Neither version is right. Salicylate chemistry was worked out across both plants at roughly the same time, in different laboratories, with results that kept converging.

The medicinal use of willow-family plants for fever and pain is very old, and the modern chain of evidence begins with the Reverend Edward Stone's 1763 report to the Royal Society on willow bark for "agues" — still the most-cited starting point for the whole story. Through the early nineteenth century, chemists in several countries isolated salicin from willow and reduced it to its active parts. In parallel, the meadowsweet distillations gave spiraeic acid. Once salicylic acid could be made synthetically and cheaply from phenol in the second half of the century, botanical sources stopped mattering commercially altogether — a detail worth holding onto, because it means the aspirin on a pharmacy shelf today has no botanical ancestry at all beyond the etymology.

Salicylic acid itself was widely used for rheumatic fever, fever and joint pain from the 1870s. It worked, and it was hard to take: sour, irritating to the throat and stomach, and unpleasant enough at effective doses that patients stopped. That intolerance is the reason anyone bothered to acetylate it. The whole point of aspirin was to make salicylate tolerable.

The human side of the 1897 synthesis is genuinely contested. The textbook account credits the young Bayer chemist Felix Hoffmann. A widely discussed 2000 reappraisal in the BMJ by the pharmaceutical historian Walter Sneader argued from the laboratory record that Arthur Eichengrün, a senior chemist whose contribution was erased under the Nazi regime because he was Jewish, had directed the work. Bayer disputes the reinterpretation. What is not disputed is the chemistry, or the fact that the tidy single-inventor story is a simplification.

Glycosides, Not Aspirin

Here is the pharmacological core of this page. When you drink meadowsweet tea, this is roughly what happens:

  1. You swallow sugar-bound salicylates and volatile esters — monotropitin, spiraein, methyl salicylate, salicylaldehyde — plus a large load of tannins and flavonoids.
  2. The sugar has to come off. Glycosides are poorly absorbed intact. Most are carried to the colon, where gut bacteria hydrolyse them. This step is slow, variable between individuals, and dependent on your microbiome.
  3. The freed aglycones are converted. Methyl salicylate is de-esterified by tissue esterases; salicylaldehyde is oxidised; the liver finishes the job. The end product circulating in your blood is salicylic acid (as salicylate anion).
  4. Nothing acetylates anything. At no point in that chain does an acetyl group appear. There is no biochemical route from a plant salicylate glycoside to acetylsalicylic acid in the human body.

The consequences of that last line are the entire reason to read this page. Salicylate and aspirin are related the way a hammer and a nail gun are related. Both drive nails. They do not behave the same way, they do not fail the same way, and you cannot substitute one for the other in a job that specifically requires the other.

Two pharmacokinetic points follow. First, the glycoside route makes onset slow and blunted. A tablet of aspirin is absorbed in the stomach and upper small intestine within minutes; a bacterial hydrolysis step in the colon takes hours and delivers a lower peak. Second, it makes the delivered dose dependent on your gut flora, which is one more reason nobody can put a number on it. The same variability has been documented for willow bark's salicin, and a 2023 paper in Pharmaceutics on the biotransformation of Filipendula ulmaria constituents looked at the gut step for meadowsweet's flavonoids rather than its salicylates: in a simulated colon, flavonoid glycosides such as rutin, spiraeoside and isoquercitrin fell while their sugar-free forms (quercetin, apigenin, naringenin and kaempferol) rose, and the extract inhibited the COX-1 enzyme more than COX-2 both before and after this processing (preliminary, in vitro).

What Acetylation Actually Does

Aspirin is not "a stronger salicylate." It has a mechanism salicylate does not have.

Aspirin's acetyl group is transferred onto a serine residue inside the substrate channel of cyclooxygenase (COX-1 and, differently, COX-2). That is a covalent, irreversible modification: the enzyme molecule is permanently disabled. The classic demonstration that aspirin-like drugs work by blocking prostaglandin synthesis was John Vane's 1971 paper in Nature New Biology, work that led to a Nobel Prize.

Salicylic acid, by contrast, is a weak and reversible COX inhibitor. Its anti-inflammatory effects at higher doses are thought to involve other pathways, including interference with inflammatory transcription signalling, rather than potent prostaglandin blockade. This is not a fringe view; it is standard pharmacology and it is why the two compounds are used for different jobs.

Three clinical consequences of acetylation, all of which matter to a reader deciding what a tea can and cannot do:

Why "Herbal Aspirin" Is a Category Error

"Herbal aspirin" is not an exaggeration; it is a mislabel. Aspirin is defined by the acetyl group. A plant that supplies salicylate precursors without it is supplying something else — a slow, low-dose, non-acetylating salicylate exposure in a matrix of tannins and flavonoids.

Calling it herbal aspirin causes two specific, opposite errors, and both are common:

The accurate framing is simple: meadowsweet is a salicylate-containing herb. It is not aspirin, and it is not aspirin-free.

Not a Substitute for Low-Dose Aspirin

This deserves its own heading because it is the one place the misunderstanding is dangerous rather than merely untidy.

If a cardiologist has put someone on 75–100 mg of aspirin daily after a heart attack, a stent or an ischaemic stroke, that prescription exists to keep platelets permanently disabled. It works because of irreversible acetylation of platelet cyclooxygenase-1 in an anucleate cell. Meadowsweet cannot produce that effect, because it does not acetylate. There is no evidence of any kind — not a trial, not an observational study, not even a decent surrogate-marker study — that meadowsweet reduces cardiovascular events.

Swapping a prescribed antiplatelet for a herbal tea is therefore not a "natural alternative." It is stopping an antiplatelet drug, which removes the platelet protection the prescription was written for, and meadowsweet does not supply that protection. If the interest is in the aspirin side of that comparison, the material on Low-Dose vs Full-Dose Aspirin and Cardiovascular Prevention covers what the trials actually showed.

The Dose Nobody Can Tell You

A fair question at this point: how much salicylate is in a cup of meadowsweet tea? The honest answer is nobody knows, and it is different every time. This is not evasion; it is the most practically useful fact in this section.

Every step of the chain adds variability:

You will see confident milligram figures quoted online. They are unreliable: published contents vary widely between analyses, tea bags and loose herb are not labelled for salicylate, and no meadowsweet product sold as a tea is standardised to a salicylate content the way a willow bark extract can be standardised to salicin.

The fact that follows is simple: the dose in a cup is unknown, so meadowsweet carries the cautions of a mild salicylate drug without the measured dose of one. Both halves of that sentence matter. A cup is not "about an aspirin," and it is not nothing.

What Each Claim Actually Rests On

Sorting this page's claims by evidence tier, since the tiers differ wildly:

Key Research Papers

Entries for a named paper link to its PubMed record; entries that describe a body of literature link to a PubMed topic search. Evidence tier is stated for each.

  1. Sneader W. "The discovery of aspirin: a reappraisal." BMJ, 2000;321(7276):1591-4. The influential re-reading of Bayer's laboratory record arguing that Arthur Eichengrün directed the acetylation work. Tier: historical scholarship. — PubMed PMID: 11124191
  2. Desborough MJR, Keeling DM. "The aspirin story — from willow to wonder drug." British Journal of Haematology, 2017;177(5):674-83. A readable review tracing salicylates through both willow and meadowsweet to the modern drug. Tier: narrative review. — PubMed PMID: 28106908
  3. Vane JR. "Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs." Nature New Biology, 1971;231(25):232-5. The foundational demonstration of the COX mechanism. Tier: established mechanism. — PubMed PMID: 5284360
  4. Literature on aspirin's irreversible acetylation of cyclo-oxygenase. The structural and biochemical work establishing covalent serine acetylation as the distinguishing feature of aspirin among salicylates. Tier: established mechanism. — Search PubMed
  5. Comparative literature on non-acetylated salicylates. Studies of salsalate and other non-acetylated salicylates, which show reduced gastric toxicity and minimal platelet inhibition relative to aspirin — the closest drug analogue to what a salicylate herb delivers. Tier: clinical pharmacology of drugs, applied to the herb by inference. — Search PubMed
  6. Van der Auwera A and colleagues. "In vitro biotransformation and anti-inflammatory activity of constituents and metabolites of Filipendula ulmaria." Pharmaceutics, 2023;15(4):1291. Follows meadowsweet's constituents, chiefly its flavonoid glycosides, through simulated gut metabolism and tests the resulting metabolites. Tier: preliminary, in vitro. — PubMed PMID: 37111776
  7. Savina T and colleagues. "Variation in phenolic compounds, antioxidant and antibacterial activities of extracts from different plant organs of meadowsweet (Filipendula ulmaria)." Molecules, 2023;28(8):3512. Documents how much the plant's chemistry differs between flowers, leaves and roots — the analytical basis for saying the dose is unstandardised. Tier: preliminary, in vitro/analytical. — PubMed PMID: 37110746
  8. Radulovic N and colleagues. "Antimicrobial synergism and antagonism of salicylaldehyde in Filipendula vulgaris essential oil." Fitoterapia, 2007;78(7-8):565-70. Identifies salicylaldehyde as a principal active constituent of the volatile oil in a close relative. Tier: preliminary, in vitro. — PubMed PMID: 17590530
  9. Analytical literature on meadowsweet's salicylate glycosides. Work characterising monotropitin (gaultherin), spiraein and related phenolic glycosides and their hydrolysis to salicylaldehyde and methyl salicylate. Tier: analytical chemistry. — Search PubMed
  10. Willow bark salicin pharmacokinetic literature. Studies tracing salicin through bacterial hydrolysis to salicylic acid, which establish the same slow, variable, microbiome-dependent route that meadowsweet's glycosides follow. Tier: human pharmacokinetics (willow, not meadowsweet). — Search PubMed
  11. Wood JN. "From plant extract to molecular panacea: a commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues’." Philosophical Transactions of the Royal Society B, 2015;370(1666):20140317. Revisits the report conventionally treated as the start of the salicylate story. Tier: historical scholarship. — PubMed PMID: 25750237
  12. Meta-analytic literature on low-dose aspirin and vascular events. The randomised-trial evidence base for antiplatelet aspirin — included here specifically to show what meadowsweet has no equivalent of. Tier: randomised controlled trials and meta-analysis (aspirin, not meadowsweet). — Search PubMed

External Resources

  1. PubMed — the biomedical literature database behind every search link above.
  2. NIH National Center for Complementary and Integrative Health — US government summaries of herb evidence and safety.
  3. MedlinePlus — plain-language drug and supplement information from the National Library of Medicine.
  4. Plants of the World Online (Kew) — authoritative source for the Spiraea ulmaria to Filipendula ulmaria name change.

Back to Table of Contents

Connections

Safety and disclaimer. Meadowsweet delivers salicylates, so the cautions that apply to aspirin broadly apply to it: salicylates can set off reactions in people sensitive to aspirin or salicylates, including aspirin-sensitive asthma; salicylate use in children and teenagers with a viral illness is linked to Reye's syndrome, a rare but serious illness that causes swelling of the liver and brain; and salicylates add to the bleeding risk of anticoagulant and antiplatelet medicines. Because the dose in a tea is unstandardised, it cannot be titrated. This page is information, not individual medical advice, and nothing here is a reason to stop or change a prescribed medicine — especially not prescribed aspirin.

Back to Table of Contents